Location:eURO Auditorium (Hall C1, Level 0)
The session deals with diagnosis and classification of patients with prostate cancer. One topic is whether genomics help us define patients with high risk disease with higher certainty and thus improve active surveillance. The other lectures deal with early diagnosis of prostate cancer, the role of multiparametric MRI and when a biopsy is indicated. Adjuvant radiotherapy is another hot topic of this session. We will learn when it should be applied.
We present the highlights of the topic "Stones" after reviewing the relevant accepted abstracts of the Congress.
The aim of the presentation is to provide an overview of the newest discoveries and best research presented within the field of Andrology at EAU 2016.
Institutes: 1University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, 2Angers University Hospital, Dept. of Urology, Angers, France, 3Rennes University Hospital , Dept. of Urology, Rennes, France, 4Université Paris-Descartes, Dept. of Urology, Paris, France, 5Centre Catalan Urologie Andrologie, Dept. of Urology, Cabestany, France, 6Besançon University Hospital, Saint Jacques Hospital , Dept. of Urology and Renal Transplantation, Besançon, France, 7Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 8LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, 9SLK Kliniken, Dept. of Urology, Heilbronn, Germany, 10Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 11Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, 12Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, 13Tampere University Hospital, Dept. of Urology, Tampere, Finland, 14Skåne University Hospital, Dept. of Urology, Malmö, Sweden, 15Andros Clinic, Dept. of Urology, Arnhem, The Netherlands, 16Stebabiotech, Medical department , Paris, France
Even if prostate biopsy is generally considered a safe procedure, it may be accompanied by several clinical complications, like bleeding or, more frequently, infective complications ranging from asymptomatic bacteriuria to symptomatic UTI and sepsis. Today, the infective complications after prostate biopsy represent an important challenge for the urologist and a life-threatening risk for the patient, in particular due to the increased rate of antibiotic resistant bacteria. We need to find novel approaches and strategies for the prevention of infective complications.
Due to early detection the life expectency for men with localized prostate cancer can be two decades or more, emphasizing the importance of long-term quality of life data. I will present long-term data focusing on the SPCG-4 study.